Correct laboratory approach to APS diagnosis and monitoring

Miyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost, 4, 295, 10.1111/j.1538-7836.2006.01753.x

Galli, 2003, Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature, Blood, 101, 1827, 10.1182/blood-2002-02-0441

Pengo, 2005, Antibody profiles for the diagnosis of antiphospholipid syndrome, Thromb Haemost, 93, 1147, 10.1160/TH04-12-0839

Pengo, 2007, A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without, Arterioscler Thromb Vasc Biol, 27, e309, 10.1161/ATVBAHA.107.153536

de Groot, 2005, Lupus anticoagulants and the risk of a first episode of deep venous thrombosis, J Thromb Haemost, 3, 1993, 10.1111/j.1538-7836.2005.01485.x

de Laat, 2004, β2-glycoprotein I dependent lupus anticoagulant highly correlates with thrombosis in the Antiphospholipid Syndrome, Blood, 104, 3598, 10.1182/blood-2004-03-1107

de Laat, 2005, IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis, Blood, 105, 1540, 10.1182/blood-2004-09-3387

Simmelink, 2003, A simple method to discriminate between beta 2-glycoprotein I- and prothrombin-dependent lupus anticoagulants, J Thromb Haemost, 1, 740, 10.1046/j.1538-7836.2003.00146.x

Pengo, 2004, A two-step coagulation test to identify anti-h2-glycoprotein I lupus anticoagulants, J Thromb Haemost, 2, 702, 10.1111/j.1538-7836.2004.00712.x

Rampazzo, 2001, Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins, Thromb Haemost, 85, 57, 10.1055/s-0037-1612904

Pengo, 2007, Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity, Thromb Res, 120, 127, 10.1016/j.thromres.2006.07.014

Harris, 1987, Anticardiolipin antibody testing: the need for standardization, Arthritis Rheum, 30, 835, 10.1002/art.1780300717

Ruffatti, 2008, Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification, J Thromb Haemost, 6, 1693, 10.1111/j.1538-7836.2008.03121.x

Mackworth-Young, 2004, Antiphospholipid syndrome: multiple mechanisms, Clin Exp Immunol, 136, 393, 10.1111/j.1365-2249.2004.02497.x

Di Simone, 2007, Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies. A review of the literature, Ann N Y Acad Sci, 1108, 505, 10.1196/annals.1422.054

Girardi, 2003, Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome, J Clin Invest, 112, 1644, 10.1172/JCI200318817

Shamonki, 2007, Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies, Am J Obstet Gynecol, 196, 167, 10.1016/j.ajog.2006.10.879

Galli, 2007, Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study, Blood, 110, 1178, 10.1182/blood-2007-01-066043

Naess, 2006, A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study), J Thromb Haemost, 4, 44, 10.1111/j.1538-7836.2005.01691.x

Runchey, 2002, Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study, Br J Haematol, 119, 1005, 10.1046/j.1365-2141.2002.03949.x

Urbanus, 2009, Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case–control study, Lancet Neurol, 8, 998, 10.1016/S1474-4422(09)70239-X

de Laat, 2009, The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study, J Thromb Haemost, 7, 1767, 10.1111/j.1538-7836.2009.03588.x

Garcia, 1997, Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with beta 2 GPI, Am J Reprod Immunol, 37, 118, 10.1111/j.1600-0897.1997.tb00200.x

Ruffatti, 2006, Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity, Thromb Haemost, 96, 337, 10.1160/TH06-05-0287

Pengo, 1997, Utilization of dilute Russell's viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids, Thromb Haemost, 77, 123, 10.1055/s-0038-1655918

Banzato, 2011, Antibodies to domain I of β2Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS), Thromb Res, 128, 583, 10.1016/j.thromres.2011.04.021

Lee, 2003, Does the anti-β2-glycoprotein I antibody provide additional information in patients with thrombosis?, Thromb Res, 111, 29, 10.1016/j.thromres.2003.08.023

Male, 2005, Predictive values of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus, Blood, 106, 4152, 10.1182/blood-2005-05-2048

Forastiero, 2005, A prospective study of antibodies to β2-GPI and prothrombin and risk of thrombosis, J Thromb Haemost, 3, 1231, 10.1111/j.1538-7836.2005.01295.x

Galli, 2010, The antphospholipid triangle, J Thromb Haemost, 8, 234, 10.1111/j.1538-7836.2009.03689.x

Pengo, 2008, Antibodies to oxidized LDL/beta2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism, Thromb Res, 122, 556, 10.1016/j.thromres.2007.12.028

Pengo, 2011, Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: a multicenter prospective study, Blood, 118, 4714, 10.1182/blood-2011-03-340232

Ames, 2005, Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation, Thromb Haemost, 93, 694, 10.1160/TH04-11-0723

Roggenbuck, 2012, Antiphospholipid antibody profiling: time for a new technical approach?, Autoimmun Rev, 11, 821, 10.1016/j.autrev.2012.02.016

Staub, 2012, Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome, Autoimmun Rev, 12, 230, 10.1016/j.autrev.2012.07.008

Pengo, 2012, High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome. “PROS” and “CONS”, Autoimmun Rev, 11, 577, 10.1016/j.autrev.2011.10.016